Aprea reports 3 of 4 patients with stable disease at 100 mg APR-1051 in Phase 1 trial

Aprea Therapeutics, Inc.

3 of 4 heavily pretreated patients achieved stable disease (RECIST v1.1) at 100 mg dose level.
Disease stabilization observed in tumors with FBXW7, CCNE1, KRAS G12V, TP53 mutations.
No dose-limiting toxicities reported; dose escalation continues at 150 mg cohort.
Poster presented at AACR-NCI-EORTC conference on Oct 24, 2025; data cutoff Sep 17, 2025.
Individual responses: rectal cancer patient on 145 days of treatment with -13% reduction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.